Welcome to LookChem.com Sign In|Join Free

CAS

  • or

226700-81-8

Post Buying Request

226700-81-8 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

226700-81-8 Usage

Description

Fosamprenavir calcium, also known as Lexiva, is an orally bioavailable prodrug of the HIV-1 protease inhibitor amprenavir. It is a highly soluble phosphate ester of amprenavir, which allows for more convenient dosing and a reduction in pill counts compared to amprenavir. Fosamprenavir calcium is typically administered in combination with other HIV drugs, such as reverse transcriptase inhibitors, for the treatment of HIV infection in adults and pediatric patients.

Uses

Used in HIV Treatment:
Fosamprenavir calcium is used as an HIV protease inhibitor for the treatment of HIV infection in adults and pediatric patients. It is particularly effective when used in combination with other antiretroviral agents, such as reverse transcriptase inhibitors. The improved solubility of fosamprenavir calcium compared to amprenavir allows for a less complex dosing schedule and fewer tablets, making it a more convenient option for patients.
Used in Initial Antiretroviral Therapy:
Fosamprenavir calcium is used as a water-soluble prodrug of amprenavir for adult and pediatric patients with HIV infection, especially as an initial antiretroviral therapy. Its improved solubility and pharmacokinetic properties make it a suitable choice for patients who are new to antiretroviral treatment.
Used in Combination Therapy with Ritonavir:
Fosamprenavir calcium is often used in combination with ritonavir, an HIV protease inhibitor, to enhance its antiviral potency and reduce the pill burden for patients. This combination therapy is typically administered at daily doses of 700–1400 mg.
Used in Monotherapy for Antiretroviral Therapy-Na?ve Patients:
In some cases, fosamprenavir calcium is used as monotherapy for antiretroviral therapy-na?ve patients. The dosing regimen for this application is 1400 mg twice daily.
Fosamprenavir calcium is used in the pharmaceutical industry for the development and formulation of HIV treatments, specifically for patients with HIV-1 infection. Its improved solubility and pharmacokinetic properties make it a valuable asset in the fight against HIV.

Originator

Vertex (US)

Clinical Use

Fosamprenavir calcium has been approved for the treatment of HIV in adults when used in combination with other anti-HIV drugs. It is a prodrug that, on hydrolysis by serum phosphatases, gives rise to amprenavir, which is a peptidomimetic transition-state inhibitor that targets HIV-1 protease and reduces the viral replication and, thus, the infectiousness of HIV-1. It is commonly administered in combination with RT inhibitors to produce excellent efficacy in patients with AIDS. The drug is administered as two 700 mg tablets twice daily or, in combination with ritonavir, can be given as two 700 mg tables once daily or one 700 mg tablet twice daily. As a result, formaprenavir lowers the "pill burden" in patients with AIDS.

Synthesis

The synthesis of fosamprenavir (X) started with a known amino alcohol 91. N,N-Dibenzyl-L-phenylalaninal (87) was prepared by reduction of L-phenylalanine (86) to L-phenylalaninol followed by N,N-dibenzylation and oxidation to the aldehyde 87 using pyridine-sulfur trioxide complex at room temperature. A large excess of lithium shot was stirred in a solution of aldehyde 87 and bromochloromethane in THF at -65°C. The reaction mixture was subsequently allowed to warm up to room temperature to provide the diastereomeric epoxide mixture (6:1) which was quenched with 6N aqueous HCl and set standing overnight to provide the salt precipitate. Recrystallization from methanol gave optically pure dibenzylaminochlorohydrin hydrochloride (88) in 38- 45% yield. Hydrogenolysis under standard conditions gave deprotected aminochlorohydrin hydrochloride 89 as a crystalline white solid. Conversion to desired N-Bocepoxide 90 was accomplished by the introduction of the Boc group followed by cyclization. N-Boc-epoxide 90 was then converted to amino alcohol 91 by refluxing with isobutylamine in EtOH. Treatment of the amino alcohol91 with p-nitrobenzene sulphonyl chloride in toluene at 80°C followed by acid hydrolysis of the Boc group furnished sulphonamide 93 in 73% yield. The carbamate 95 was prepared by refluxing 93 with (S)-tetrahydrofuryl imidazole carboxylate (94) in EtOAc. Treatment of the sulphonamide 95 with POCl3 followed by aqueous HCl hydrolysis provided the phosphate intermediate, which was then reduced by hydrogenation and converted to fosamprenavir calcium salt X in a one-pot process in 92% yield.

Drug interactions

Potentially hazardous interactions with other drugs Anti-arrhythmics: possibly increased concentration of amiodarone, flecainide, lidocaine and propafenone (increased risk of ventricular arrhythmias) - avoid. Antibacterials: increases concentration of rifabutin - reduce rifabutin dose; concentration significantly reduced by rifampicin - avoid; avoid with telithromycin in severe renal and hepatic impairment. Anticoagulants: avoid with apixaban and rivaroxaban. Antidepressants: concentration reduced by St John’s wort - avoid. Antimalarials: use artemether/lumefantrine with caution; possibly increases quinine concentration. Antipsychotics: possibly inhibits aripiprazole metabolism - reduce aripiprazole dose; possibly increases quetiapine concentration - avoid; possibly increases pimozide concentration (increased risk of ventricular arrhythmias) - avoid. Antivirals: avoid with boceprevir, raltegravir and telaprevir; concentration of dolutegravir reduced; concentration increased by etravirine, consider reducing fosamprenavir dose; concentration reduced by lopinavir, maraviroc and tipranavir, effect on lopinavir unpredictable - avoid, avoid with maraviroc; concentration possibly reduced by nevirapine; avoid with raltegravir. Anxiolytics and hypnotics: increased risk of prolonged sedation and respiratory depression with midazolam - avoid with oral midazolam. Avanafil: concentration of avanafil possibly increased. Cytotoxics: possibly increases concentration of bosutinib and ibrutinib, avoid or consider reducing bosutinib and ibrutinib dose. Ergot alkaloids: increased risk of ergotism - avoid. Immunosuppressants: monitor ciclosporin, tacrolimus and sirolimus levels. Lomitapide: avoid concomitant use. Orlistat: absorption possibly reduced by orlistat. Ranolazine: possibly increases ranolazine concentration - avoid. Statins: possibly increased risk of myopathy with atorvastatin; possibly increased myopathy with simvastatin and rosuvastatin - avoid.

Metabolism

Fosamprenavir is rapidly and almost completely hydrolysed to amprenavir and inorganic phosphate as it is absorbed through the gut epithelium, following oral administration. The primary route of metabolism of amprenavir is via the cytochrome P450 3A4 enzyme. The primary route of elimination of amprenavir is via hepatic metabolism with less than 1% excreted unchanged in the urine and no detectable amprenavir in faeces. Metabolites account for approximately 14% of the administered amprenavir dose in the urine, and approximately 75% in the faeces.

references

[1]. wire, m.b., et al., pharmacokinetics and safety of gw433908 and ritonavir, with and without efavirenz, in healthy volunteers. aids, 2004. 18(6): p. 897-907.[2]. hamada, y., et al., high incidence of renal stones among hiv-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy. clin infect dis, 2012. 55(9): p. 1262-9.[3]. zheng, y., et al., antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens. clin infect dis, 2014. 59(6): p. 888-96.[4]. falcoz, c., et al., pharmacokinetics of gw433908, a prodrug of amprenavir, in healthy male volunteers. j clin pharmacol, 2002. 42(8): p. 887-98.

Check Digit Verification of cas no

The CAS Registry Mumber 226700-81-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,2,6,7,0 and 0 respectively; the second part has 2 digits, 8 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 226700-81:
(8*2)+(7*2)+(6*6)+(5*7)+(4*0)+(3*0)+(2*8)+(1*1)=118
118 % 10 = 8
So 226700-81-8 is a valid CAS Registry Number.
InChI:InChI=1/C25H36N3O9PS.Ca/c1-18(2)15-28(39(33,34)22-10-8-20(26)9-11-22)16-24(37-38(30,31)32)23(14-19-6-4-3-5-7-19)27-25(29)36-21-12-13-35-17-21;/h3-11,18,21,23-24H,12-17,26H2,1-2H3,(H,27,29)(H2,30,31,32);/q;+2/t21-,23-,24+;/m0./s1

226700-81-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 16, 2017

Revision Date: Aug 16, 2017

1.Identification

1.1 GHS Product identifier

Product name Fosamprenavir calcium

1.2 Other means of identification

Product number -
Other names calcium [(3s)-oxolan-3-yl] n-[(2s,3r)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-1-phenyl-3-phosphonatooxy-butan-2-yl]carbamate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:226700-81-8 SDS

226700-81-8Upstream product

226700-81-8Downstream Products

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 226700-81-8